Product Description
Mechanisms of Action: Voltage-Gated Potassium Channel Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Sweden
Approved Indications: None
Known Adverse Events: None
Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atrial Fibrillation|Atrial Flutter
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
S219.3.118 | P3 |
Completed |
Atrial Flutter|Atrial Fibrillation |
2006-03-01 |
|
S219.3.116 | P3 |
Completed |
Atrial Flutter|Atrial Fibrillation |
2006-03-01 |
|
S219.3.117 | P3 |
Completed |
Atrial Flutter|Atrial Fibrillation |
2006-01-01 |
|
2004-000346-21 | P3 |
Active, not recruiting |
Atrial Fibrillation|Atrial Flutter |
2005-03-06 |